

AREN-11.US9.DIV (0239)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: C. Liaw et al. : Art Unit: 1646  
Serial No.: 09/875,076 : Examiner: P. Mertz  
Filed: June 6, 2001 : Confirmation No.: 6379  
For: NUCLEIC ACID ENCODING :  
HUMAN G PROTEIN-COUPLED  
RECEPTOR

Via Express Mail Label No: EV147590461US  
Date Sent: February 20, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R :

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit herewith several references filed in related, non-priority cases. Applicants' respectfully submit that these references are being submitted contemporaneously with the issue fee. The references are being submitted in view of Applicants' duty of candor although Applicants' believe they are not material to the claimed invention. The references are being submitted only because of the relationship of the applications to one another, although different subject matter is claimed in each. It is our understanding that these references will be placed in the permanent file. A copy of each listed reference is also enclosed.

This submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

03/09/2004 SLUANG1 00000001 501275 09875076

01 FC:1806 180.00 DA

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Please charge the required fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1275.

Respectfully submitted,



---

Michael A Patané  
Registration No. 42,982  
Attorney for Applicants


Enclosures:

Form PTO/SB/08B

Copy of References Cited

Dated: February 20, 2004

Cozen O'Connor  
1900 Market Street – 5<sup>th</sup> Floor  
Philadelphia, PA 19103  
Tel: 215-665-2000  
Fax: 215-665-2013



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

2

**Complete if Known**

|                        |              |
|------------------------|--------------|
| Application Number     | 09/875,076   |
| Filing Date            | June 6, 2001 |
| First Named Inventor   | Ruoping Chen |
| Art Unit               | 1646         |
| Examiner Name          | Prema Mertz  |
| Attorney Docket Number | 11.US9.DIV   |

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                        | AA                       | US-2003/0125539 A1                         | 07/03/2003                     | Bonini et al                                       |   |
|                        | AB                       | US- 2003/0064381                           | 04/03/2003                     | Bonini et al                                       |   |
|                        | AC                       | US- 6,468,756                              | 10/22/2002                     | Bonini et al                                       |   |
|                        | AD                       | US- 6,221,660                              | 04/24/2001                     | Bonini et al                                       |   |
|                        | AE                       | US- 5,932,445                              | 08/03/1999                     |  |   |
|                        | AF                       | US 2003/0180813                            | 09/25/2003                     |  |   |
|                        | AG                       | US-2003/0139590                            | 07/24/2003                     |  |   |

**FOREIGN PATENT DOCUMENTS**


| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|-----------------------|--------------------------|---|-----------------------------------|---|--|----------------|
|                       |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                   |   |  |                |
|                       | BA                       | EP 1 092 727 A2   | 01/18/2001                        | Pfizer Limited et<br>al                               |  |                |
|                       | BB                       | WO 01/32864 A1  | 02/10/2001                        | Merck Patent<br>GMBH et al                            |  |                |
|                       | BC                       | WO 01/87929 A2  | 11/22/2001                        | Bayer<br>Aktiengesellschaft<br>et al.                 |  |                |
|                       | BD                       | WO 00/31258 A2  | 06/02/2000                        | Arena<br>Pharmaceuticals<br>Inc., et al               |  |                |
|                       | BE                       | WO 01/36473 A2  | 05/25/2001                        | Pharmacia &<br>Upjohn Co.                             |  |                |
|                       | BF                       | WO 00/50562   | 08/31/2000                        | Synaptic<br>Corporation                               |  |                |
|                       | BG                       | WO 01/42288 A2  | 06/14/2001                        | Incyte Genomics,<br>Inc.                              |  |                |
|                       | BH                       | WO 02/186548 A2<br>(W/ English Abstract)  | 02/28/2002                        | Japan Science<br>and Technology<br>Corporation        |  |                |
|                       | BI                       | WO 02/0244362 A1<br>(w./ English Abstract)  | 06/06/2002                        | Yamanouchi<br>Pharmaceutical<br>Co., Ltd.             |  |                |
|                       | BJ                       | EP 1338651  | 08/27/2003                        | Yamanouchi<br>Pharmaceutical<br>Co. Ltd.              |  |                |
|                       | BK                       |   |                                   |   |  |                |
|                       | BL                       |   |                                   |   |  |                |
|                       | BM                       |   |                                   |   |  |                |

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

**Complete if Known**

|                        |              |
|------------------------|--------------|
| Application Number     | 09/875,076   |
| Filing Date            | June 6, 2001 |
| First Named Inventor   | Ruoping Chen |
| Group Art Unit         | 1646         |
| Examiner Name          | Prema Mertz  |
| Attorney Docket Number | 11.US9.DIV   |

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
|                        | CA                       | Bentley, "Genomic sequence information should be release immediately and freely to the public," The Sanger Institute: Human Genome Project, Policy Forum, Science (1996) 274:533-534.   |                |
|                        | CB                       | The Sanger Institute: Data Release Policy, www.sanger.ac.uk, May 24, 2002.  |                |
|                        | CC                       | Genbank Acc. #AL035423, update version of February 12, 1999.  |                |
|                        | CD                       | Genbank Acc #AL035423, update version of February 24, 1999.   |                |
|                        | CE                       | Genbank Acc. #AL035423, update version of February 27, 1999.  |                |
|                        | CF                       | Genbank Acc. #AL035423, update version of April 21, 1999  |                |
|                        | CG                       | Genbank Acc. #AL035423, update version of November 23, 1999.  |                |
|                        | CH                       | Sequence Revision History for Genbank Acc. #AL035423.   |                |
|                        | CI                       |   |                |
|                        | CJ                       |   |                |
|                        |                          |   |                |

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.